• Policy
• DPK urges doctors to return to work
• by Lee, Jeong-Hwan Mar 7, 2024 07:16am

• Policy
• High-strength Ebixa generics start receiving approval again
• by Lee, Hye-Kyung Mar 7, 2024 07:16am

• Policy
• Once-weekly growth hormone Sogroya is approved in Korea
• by Lee, Hye-Kyung Mar 7, 2024 07:16am

• Company
• Oral PNH drug Fabhalta to soon be released in Korea
• by Eo, Yun-Ho Mar 7, 2024 07:15am

• Policy
• The RSA track to include drugs for chronic diseases, asthma
• by Lee, Tak-Sun Mar 7, 2024 07:15am

• Opinion
• [Reporter’s View] On MFDS’s new drug management team
• by Lee, Hye-Kyung Mar 6, 2024 06:03am

• Company
• Rare drug Ultomiris posts KRW 40 billion in sales in 3 yrs
• by Nho, Byung Chul Mar 6, 2024 06:03am

• Company
• Reimb for Verzenio in early breast cancer undergoes review
• by Eo, Yun-Ho Mar 6, 2024 06:03am

• Company
• Cash cow ‘bepotastine’ to face reimb re-evaluation
• by Chon, Seung-Hyun Mar 6, 2024 06:02am

• Company
• Dupixent, 1st biologic approved for pruritic rash indication
• by Son, Hyung-Min Mar 5, 2024 05:49am